FDA rejects Eli Lilly’s eczema drug due to third-party manufacturing issues
FDA has rejected Eli Lilly’s eczema treatment lebrikizumab due to issues found at an unnamed third-party manufacturer.
According to a press …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
